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Background: The projected demand for total knee arthroplasty is staggering. At its root, the solution involves
increasing supply or decreasing demand. Other developed nations have used rationing and wait times to distribute
this service. However, economic impact and cost-effectiveness of waiting for TKA is unknown.
Methods: A Markov decision model was constructed for a cost-utility analysis of three treatment strategies for
end-stage knee osteoarthritis: 1) TKA without delay, 2) a waiting period with no non-operative treatment and
3) a non-operative treatment bridge during that waiting period in a cohort of 60 year-old patients. Outcome
probabilities and effectiveness were derived from the literature. Costs were estimated from the societal perspective
with national average Medicare reimbursement. Effectiveness was expressed in quality-adjusted life years (QALYs)
gained. Principal outcome measures were average incremental costs, effectiveness, and quality-adjusted life years;
and net health benefits.
Results: In the base case, a 2-year wait-time both with and without a non-operative treatment bridge resulted in a
lower number of average QALYs gained (11.57 (no bridge) and 11.95 (bridge) vs. 12.14 (no delay). The average cost
was $1,660 higher for TKA without delay than wait-time with no bridge, but $1,810 less than wait-time with
non-operative bridge. The incremental cost-effectiveness ratio comparing wait-time with no bridge to TKA without
delay was $2,901/QALY. When comparing TKA without delay to waiting with non-operative bridge, TKA without
delay produced greater utility at a lower cost to society.
Conclusions: TKA without delay is the preferred cost-effective treatment strategy when compared to a waiting for
TKA without non-operative bridge. TKA without delay is cost saving when a non-operative bridge is used during
the waiting period. As it is unlikely that patients waiting for TKA would not receive non-operative treatment, TKA
without delay may be an overall cost-saving health care delivery strategy. Policies aimed at increasing the supply of
TKA should be considered as savings exist that could indirectly fund those strategies.
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Total knee arthroplasty (TKA) is an effective treatment
to alleviate pain and improve physical functioning in pa-
tients with arthritic knees [1]. Approximately 300,000
TKAs are performed in the United States each year
making it an exceptionally common surgical procedure
[2]. As the population continues to age, the demand for
primary TKAs is projected to increase 673% by 2030 [3].
Others have projected significant workforce shortages
poised to meet this growing demand [4,5]. Undoubtedly,
great challenges about how to narrow this gap in supply
and demand are upon us.
Strategies to meet this demand include workforce
increases, operational efficiency gains and minimizing
revisions. However, experience from other developed
countries as well as the U.S. Veterans Administration
Hospital system suggest wait times will increase rapidly
as demand rises. The current mean wait time for TKA
in Canada is 237 days and the mean wait time for TKA
within the Veterans Affairs Healthcare System in the
United States can be as long as two years [6,7]. In par-
ticular the wait time in Canada has grown by 423% since
the mid-1990s. Furthermore, increased waiting time for
TKA has the potential to negatively impact patient out-
come. Wait times longer than 6 months may reduce
health-related quality of life and increase contralateral
knee pain 6 months after TKA [8,9].
TKA is known to be a cost-effective treatment across
populations in the United States and abroad [10-12].
Furthermore, end-stage arthritis is associated with high
direct medical costs and healthcare resource utilization
[13,14]. However, the societal economic impact of
wait times for elective procedures remains unclear. A
complete understanding of the entire care pathway of
end-stage OA is necessary to direct policymaking and
optimizes resource allocation. Using the power of deci-
sion analysis, the purpose of this study was to explore




The decision model and analysis in this study was per-
formed in accordance with the consensus-based recom-
mendations for the conduct of cost-effectiveness analysis
advocated by the Panel on Cost-Effectiveness in Health
and Medicine [15-17]. The model compared three pos-
sible treatment arms for a patient age 60 with end-stage
knee OA requiring TKA. Two scenarios were examined
in the base case, (A) direct medical costs only and (B)
direct + indirect costs. The analysis was performed with
a decision tree using a general decision analysis software
package (TreeAge Pro Suite 2011; TreeAge Software
Inc., Williamstown, Massachusetts).Decision model
A Markov health state decision model was created for
the treatment of end-stage knee OA [18]. The decision
tree consists of three principal treatment arms, or strat-
egies: TKA without delay, delayed TKA with non-
operative bridge treatment and delayed TKA with no
bridge treatment. A simplified schematic of the model is
shown in Figure 1. Both treatment arms and transition
probabilities are consistent in design to those previously
published in the literature [19-22].
After undergoing TKA individuals remain in an initial
post-procedure state for one month, either surviving or
dying based on all cause or perioperative mortality
(Table 1). Perioperative complications were not directly
modeled. No revisions can occur until the end of year
one. All patients then transition to well TKA, represen-
tative of the average outcome after TKA. This cohort of
patients will subsequently remain in TKA until they die
of natural causes or undergo revision TKA. Patients can
undergo two revision TKAs.
The delayed treatment remains in the end-stage OA
health-state until the predetermined wait time has ex-
pired, set as 2 years in the base case. Patients receiving
the non-operative bridge can experience partial symp-
tom relief during the waiting period, while the non-
bridge patients remain at the baseline end-stage knee
OA utility.
Health states were assigned a health utility and cost
value. Utility values are numeric values assigned to
health states annually based on the commonly accepted
reference values of 1 being “full health” and 0 being
“death” [23]. These values are used to estimate quality-
adjusted life years (QALYs), the measure of effectiveness
reported in cost-utility analyses. Utility values for health
states can be derived by either direct methods, such as
time tradeoff and rating scales, or indirect methods,
where health status instruments such as the Quality
of Well-Being Scale are mapped to a numeric value
between 0 and 1 based respondent answers to various
attributes. Health state utility values for a wide variety of
conditions have been assessed using a combination of
these methods and are available in catalogued disease-
specific format to provide a basis quality of life measure-
ments in cost-effectiveness analyses [24-26]. Cost values
were assigned for the primary intervention and subse-
quent revision procedures as the surviving cohort transi-
tions to alternate health states based on the assigned
transition probabilities. The cycle length used in this
model was one month. As the theoretical patient cohort
cycles through the model, costs and utilities are accumu-
lated on a per monthly basis over the lifetime of the
cohort until all members of the cohort have died.
Consistent with accepted healthcare decision analysis
methods, future costs and utilities were discounted at
Figure 1 Health state diagram. The figure shows the health state diagram used to model patients undergoing either TKA without delay,
delayed TKA with non-operative bridge treatment, or delayed TKA with no bridge treatment. The diagram reflects the distinct health states in
the model.
Table 1 Model parameters
Health state utility (QALY) Base case Sensitivity analysis
End-stage Knee OA 0.6 0.4-0.8
End-stage knee OA with treatment bridge 0.7 0.6-0.9
Primary TKA 0.9 0.6-0.9
Revision TKA 0.85 0.6-0.9
Recovery from revision TKA -0.1 -0.25-0
Recovery from early TKA complication -0.20 -0.40-0
Transition probabilities
Early complication after TKA 0.01 0-0.05
Failure to revision of primary TKA (annual)
Years 0-9 0.005 0-0.02
Years 10-19 0.01 0-0.05
Years 20+ 0.02 0-0.05
Failure to revision of revision TKA (annual)
Years 0-9 0.01 0-0.04
Years 10-19 0.02 0-0.08
Years 20+ 0.04 0-0.10
All-cause mortality Life Tables None
30-Day mortality after primary TKA 0.007 0-0.014
30-Day mortality after revision TKA 0.01 0-0.02
Wait for TKA 2 years 3 weeks to 5 years
Costs
Indirect costs of knee OA $10,369 0-$20,000
Direct costs of knee OA (Non-operative Treatment Bridge) $2,500 0-$3,883
Primary TKA $26,865 $20,000-$30,000
Revision TKA $35,542 $30,000-$40,000
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was used to evaluate the total accumulated costs and
effectiveness, measured in QALYs, of each treatment
strategy to evaluate the overall cost-effectiveness of im-
mediate primary TKA compared to delayed primary
TKA for end-stage knee OA as the primary outcome in
this patient cohort analysis.
Non-arthroplasty bridge
Several non-arthroplasty bridge-to-TKA treatment options
were examined. They were assumed to provide some
symptomatic relief, but to fall short of that achieved by
primary TKA. These consisted of corticosteroid injection,
viscosupplementation, physical therapy, and non-steroidal
anti-inflammatory drugs including both non-selective and
COX-2 inhibitors. In the base case, patients treated with a
non-operative bridge were assumed to experience a 33%
improvement in utility for the entire delay before TKA.
Alternative outcomes including full symptomatic relief for
one quarter of the waiting period were examined with
sensitivity analysis.
Decision model assumptions
Several important assumptions were made in the construc-
tion of this model and require identification. First, we
assumed the patient population defined in the model to be
a theoretical cohort of healthy patients aged 60 years with
end-stage knee OA treated non-operatively prior to pos-
sible TKA. This cohort is assumed to have already un-
dergone and failed appropriate non-operative measures
as outlined by the American Academy of Orthopaedic
Surgeons Clinical Practice Guidelines on Treatment of
Osteoarthritis of the Knee (Non-Arthroplasty) [27]. Second,
we assumed the non-operative bridge would consist of
treatments at the average cost for OA as measured by the
Medical Expenditures Survey. Third, we assumed the non-
operative bridge would not avoid the need for TKA as these
patients had already failed all non-operative treatment and
were considered candidates for primary TKA. Fourth, we
assumed the all-cause mortality of patients in the theoret-
ical cohort following recovery from a surgical intervention
to be equal to that of the general population. Fifth, we
did not directly model post-operative complications. We
assumed all patients recover to the average outcome from
TKA at the end of the first year and cannot undergo
revision until 1 year post-op. The cost values used in the
model included all costs 90 days from surgery, which




We used a Markov decision model to analyze a theoret-
ical cohort of 60-year-old patients with knee OA. Thecohort age was set at 60 years consistent with the mean
age from our literature review (Table 1) [2,6].
Mortality rates
The probability of perioperative death for patients
undergoing TKA has been used in prior publication,
which was estimated from a study of the Medicare
population as 90-day mortality of 0.07 with revision knee
replacement at 0.11 [28]. Life expectancy and all-cause
mortality rates were obtained from age-specific life ta-
bles [29].
Utilities
Utility values for each health state were assigned based
on heath-related quality of life outcome. End-stage arth-
ritis has consistently been shown to have a utility value
near 0.6 [24-26]. We defined 100% improvement from
non-arthroplasty treatment as 0.9. This is consistent
with other arthroplasty studies and utility studies on re-
covery from knee pain [22]. We assigned utility values
for TKA and revision TKA that have been validated and
are consistent with prior publications in the orthopaedic
literature [10,12,21,22]. Utility values used for all health
states in the model are shown in Table 1.
“Disutility” values represent the short-term negative
impact an intervention has on a patient’s quality of life
[23]. With surgical procedures, this can include pain,
immobility, and non-lethal surgical complications in the
post-operative and recovery periods. These transient pe-
riods of disutility are accounted for as a one-time deduc-
tion from the health-related quality of life value gained
by the patient in the year of procedure. We calculated a
disutility value using the time to recovery and quality of
life during recovery. Our calculated values were similar
to those used in previous Markov decision analyses
[22,30] with TKA -0.1, revision due to infection -0.2, and
revision TKA due to a disutility of -0.15. Disutility values
used in the model are also shown in Table 1. No disutil-
ity for non-arthroplasty treatment was modeled.
Costs
We used 2009 5% Medicare claims data to compute the
direct medical cost of surgical treatment. We used ICD-
9 diagnosis code “715.x6” to identify patients admitted
to a hospital with a primary diagnosis of osteoarthritis of
the knee. The following ICD-9 procedure codes were
used to identify the relevant surgical techniques: “81.54”
for total knee arthroplasty and “81.55,” “00.80,” “00.81,”
“00.82,” “00.83,” and “00.84” for revision knee arthro-
plasty. The direct model costs include inpatient cost,
physician cost and the costs from post-acute care facil-
ities, such as skilled nursing facility, hospice, home
health service, inpatient rehabilitation facility and long-
term care hospitals. For post-acute care costs, we first
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ent post-acute care facilities and the average cost of each
type of post-acute care facility. We then compute the
weighted average cost across all post-acute care facilities.
These costs were tracked for 3 months after surgery.
Additionally, the costs of 18 physical therapy visits
were included as part of rehabilitation costs associated
with TKA or TKA Revision. These costs, based on a
Medicare population were adjusted to a private payer
population.
The cost for the non-operative treatment bridge was
taken from the Medical Expenditures Survey [31]. The
number and type of treatments are likely to vary widely
in actual practice and the mean societal value was felt to
be an appropriate approximation. Lastly, in scenario B
we included indirect costs associated with end-stage
knee OA and after primary TKA. These include items
such as lost earnings and productivity, caregiver costs,
etc. These values were also taken from the MES [31].
Patients were assumed to recover 80% of the indirect
costs of end-stage knee OA after successful primary
TKA [32]. These costs can be found in Table 1.
Cost-effectiveness analysis
The Markov model was used to conduct a cost-
effectiveness analysis of the decision process for non-
arthroplasty treatment of knee OA. The present-day
value of the expected costs and QALYs gained over the
lifetime of a theoretical patient cohort was calculated
based on treatment strategy. Outcome measures in-
cluded average costs and effectiveness (QALYs), as well
as the cost-effectiveness (C/E) ratio for each strategy.
The incremental costs and effectiveness were also calcu-
lated and represent the relative difference between the
two alternative strategies. The principle outcome
measurement calculated was the incremental cost-
effectiveness ratio (ICER), which is the ratio between the
difference in costs and difference in QALY of each strat-
egy. In terms of this model, the ICER could be expressed
as ICER = (CostTKA without delay – Costdelayed TKA) /
(QALYsTKA without delay – QALYdelayed TKA). ICERs less
than $50,000 per QALY gained were considered to be
cost-effective based on a willingness of the health-care
system to pay (WTP) value of $50,000. In this cost-
effectiveness analysis, the preferred treatment strategy
was the most effective strategy with an ICER < WTP.
One, two and three way sensitivity analyses were per-
formed on all variables in the model. Variables deemed
sensitive are those who when variable across a reason-
able range change the preferred strategy. If the preferred
strategy does not change, then the variable is termed
robust.
This study was approved by the Duke University
Health System’s Institutional Review Board.Results
Base case
In the base case, a 2-year wait-time both with and with-
out a non-operative treatment bridge resulted in a lower
number of average quality-adjusted life-years gained
(11.57 QALY (no bridge) and 11.76 QALY (bridge) vs.
12.18 QALY (no delay). The average cost to society was
$2,920 higher for TKA without delay than a 2 year wait-
time with no bridge, but $2,143 less than a wait-time
with a non-operative treatment bridge. The incremental
cost effectiveness ratio comparing wait-time with no
bridge to TKA without delay was $4,768/QALY, below
the willingness-to-pay threshold of $50,000/QALY.
When comparing TKA without delay to waiting with
a non-operative bridge, TKA without delay produced
greater utility for the patient at a lower cost to society,
therefore, dominating the waiting with non-operative
bridge strategy for the treatment of knee osteoarthritis.
However, when indirect costs are included, TKA with-
out delay produces greater utility at a lower cost to soci-
ety than either wait-time strategy. The incremental cost
of delayed TKA with a non-operative bridge rises to
$18,900 and $13,836 for delay without the treatment
bridge. Utility remains the same. The results of the base
case are found in Table 2.
Sensitivity analysis
Multivariate sensitivity analyses demonstrated that all
variables were robust with cost effectiveness as the out-
come measure. Only when the utility of primary TKA
falls below the utility of knee pain would either of the
delayed scenarios become preferred. When considering
cost as the outcome, if a patient experiences $151.57/
month or greater (base case = $857) of indirect costs
such as lost wages or caregiver expenses, TKA without
delay becomes less costly and, therefore, a dominant
treatment strategy. Similarly, if the cost of the non-
operative bridge falls below $294/month, it becomes less
costly than TKA without delay, but TKA without delay
is still the preferred cost effective strategy. When evalu-
ating the non-operative bridge only compared to no
treatment, if the patient receives 13 months or more of
symptomatic relief with the bridge while waiting for a
TKA, then the bridge is the preferred cost effective strat-
egy if TKA without delay is not available. The ability
of TKA to reduce the indirect costs associated with
end-stage knee OA is an important variable – TKA
without delay is less costly than a 2 year wait-time when
TKA reduces 15% or more of these indirect costs.
Figure 2 shows the effect of increasing wait times on
net health benefits. As wait times increase, net health
benefits fall precipitously. In Figure 3, the future societal
costs of delayed TKA are estimated using the projections
established by Kurtz et al [3]. The cost scenario using















A TKA without delay $17,840 12.18 $1,667 0.61 $1,464/QALY $2,723/QALY
Delayed TKA with
Nonop Bridge
$21,230 11.76 $3,398 0.19 $1,806/QALY $17,880/QALY*
Delay + No Bridge $16,170 11.57 - - $1,398/QALY -
B TKA without delay $59,640 12.18 - 0.61 $4,897/QALY
Delayed TKA with
Nonop Bridge
$78,541 11.76 $18,900 0.19 $6,679/QALY DOMINATED**
Delay + No Bridge $73,477 11.57 $13,836 - $6,351/QALY DOMINATED**
Cost scenario A = Direct costs only, Cost scenario B = Indirect costs included
*Waiting with a non-operative bridge resulted in a lower number of average quality-adjusted life-years gained while also at a higher average cost to the payer
and is, therefore, “DOMINATED” by the TKA without delay strategy for the treatment of end-stage knee osteoarthritis in the base case. It is considered cost
effective compared to delayed TKA with no treatment bridge.
**When indirect costs are considered, TKA without delay is both less costly and more effective than the other two strategies and is therefore a dominant
treatment strategy.
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operative bridge is shown. Per patient, for a wait time of
6 months and 5 years, the incremental cost is $5,652
and $42,832 respectively. In the year 2020, this translates
to an incremental cost of $8.59 billion for a wait time of
6 months. If the wait time were to soar to 5 years, the
incremental cost in 2030 would reach nearly $150 billion
(149.1). The impact on quality of life is substantial as
well – in the year 2020 for a wait time of 2 years, TKA
without delay results in an additional 927,200 QALYs or
years of perfect health related to end-stage knee OA.
Discussion
Delaying primary TKA for patients who have failed all
non-operative treatments for end-stage knee OA appears
to be an inefficient strategy. Immediate primary TKA for
end-stage knee OA is the preferred cost effective strat-
egy concerning the timing of the delivery of primary
TKA. Compared to the 2-year waiting period modeled
in the base case, TKA without delay was a dominantFigure 2 Sensitivity analysis on potential wait times with net benefits
analysis on wait times up to 60 months for primary TKA with net benefits atreatment strategy when indirect costs are included or
when a non-operative bridge costing over $87 per
month is used during the waiting period.
Extrapolating these costs to the estimates for the de-
mand for primary TKA shows staggering results. Within
10 years expanding wait times could be responsible for
an additional $10-$80 billion. Within 20 years this num-
ber could reach $84 billion in annual incremental costs
using the base case wait time of 2 years. In the worst
case scenario of a 5-year wait time, incremental costs
could approach $200 billion.
Wait times for primary total joint arthroplasty have
already begun to rise. The wait time in Canada has
grown by 437% since the mid 1990s and is now over 6
months, the critical period where health-related quality
of life is adversely affected. The problem extends beyond
orthopaedic surgery and the U.S. – In a 5 country ana-
lysis in 2002, Blendon et al. reported that the percentage
of patients waiting greater than 4 months for any elect-
ive surgery increased by at least 4% during a 3 yearas outcome. The graph shows the results of a one-way sensitivity
s the outcome.
Figure 3 Societal economic impact of potential wait times. The figure shows the estimated future societal costs of delayed TKA. Values are
costs only and do not include monetary value of utility. These values represent the incremental cost of each wait time with non-operative
treatment bridge compared to TKA without delay baseline. They are extrapolated from data from out model combined with volume projections
from Kurtz et al. [3].
Mather et al. BMC Musculoskeletal Disorders 2014, 15:22 Page 7 of 8
http://www.biomedcentral.com/1471-2474/15/22period in all 5 major countries that he examined [33].
Wait times in the U.S. have not been examined recently
but were measured at only 3 weeks in 1994.
The impact of these findings suggests that policy-
makers should make concerted efforts to support the
development of innovative strategies and expansion of
existing ones to meet demand. Increasing the size of the
workforce has been discussed and projections in Canada
suggest that the annual supply of surgeries must increase
by 12% or greater each year to prevent further increases
in mean waiting times [34]. Payment reform must also
be carefully crafted to incentivize appropriate utilization.
Lastly, decisions must be made with consideration of the
entire healthcare system and avoid too narrow of a focus
on one disease.
The weaknesses of this study include primarily the es-
timation of costs. We utilized Medicare reimbursement,
an accepted approach for cost effectiveness analysis. This
approach may not capture the complete cost of care, but
sensitivity analysis revealed the cost of primary TKA was
robust. As such, the inaccuracies of cost estimation
would not affect the preferred treatment. Greater uncer-
tainty surrounds the reduction in indirect costs after
TKA. While the indirect costs of end-stage OA are well-
studied, the ability of TKA to reduce these costs is less
known. Several studies have investigated return to work
after primary total joint arthroplasty [35], but only one
examined TKA and reported a return to work after 30-
day rate of 82% [29]. In the base case we assumed an
80% reduction in indirect costs, but rigorous sensitivityanalysis was performed, demonstrating that TKA with-
out delay becomes less costly when 15% or more of
these costs are affected. As this number is well below
the lowest number reported in the literature, the reduc-
tion in indirect costs after primary TKA is practically
robust. However, this assumption needs further study to
provide a more accurate projection of the total societal
cost of wait times.
Conclusions
In summary, minimizing wait times for primary TKA is
cost effective and may be cost saving. It clearly increases
utility for the patient, but the cost implications are less
clear due to estimates of indirect costs. However, the
threshold of indirect cost where TKA is cost saving as-
suming a 2-year wait time is low and well below most
published estimates. Policymakers cannot ignore the
societal impact of diminished access to total knee
arthroplasty.
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